Literature DB >> 29939181

A Protocol to Acquire the Degenerative Tenocyte from Humans.

Soo-Hong Han1, Hyung Kyung Kim2, Jong-Ho Ahn1, Dong Hyeon Lee3, Minjung Baek1, Geunhee Ye1, Joong-Myung Lee1, Kyunghoon Min4, Chihoon Oh1, Soonchul Lee5.   

Abstract

Tendinopathy, a painful condition that develops in response to tendon degeneration, is on the rise in the developed world due to increasing physical activity and longer life expectancy. Despite its increasing prevalence, the underlying pathogenesis still remains unclear, and treatment is generally symptomatic. Recently, numerous therapeutic options, including growth factors, stem cells, and gene therapy, were investigated in hopes of enhancing the healing potency of the degenerative tendon. However, the majority of these research studies were conducted only on animal models or healthy human tenocytes. Despite some studies using pathological tenocytes, to the best of our knowledge there is currently no protocol describing how to obtain human degenerative tenocytes. The aim of this study is to describe a standard protocol for acquiring human degenerative tenocytes. Initially, the tendon tissue was harvested from a patient with lateral epicondylitis during surgery. Then biopsy samples were taken from the extensor carpi radialis brevis tendon corresponding to structural changes observed at the time of surgery. All of the harvested tendons appeared to be dull, gray, friable, and edematous, which made them visually distinct from the healthy ones. Tenocytes were cultured and used for experiments. Meanwhile, half of the harvested tissues were analyzed histologically, and it was shown that they shared the same key features of tendinopathy (angiofibroblastic dysplasia or hyperplasia). A secondary analysis by immunocytochemistry confirmed that the cultured cells were tenocytes with the majority of the cells having positive stains for mohawk and tenomodulin proteins. The qualities of the degenerative nature of tenocytes were then determined by comparing the cells with the healthy control using a proliferation assay or qRT-PCR. The degenerative tenocyte displayed a higher proliferation rate and similar gene expression patterns of tendinopathy that matched previous reports. Overall, this new protocol might provide a useful tool for future studies of tendinopathy.

Entities:  

Mesh:

Year:  2018        PMID: 29939181      PMCID: PMC6101647          DOI: 10.3791/57634

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  28 in total

1.  Insulin-like growth factor-I improves cellular and molecular aspects of healing in a collagenase-induced model of flexor tendinitis.

Authors:  Linda A Dahlgren; Marjolein C H van der Meulen; John E A Bertram; Greg S Starrak; Alan J Nixon
Journal:  J Orthop Res       Date:  2002-09       Impact factor: 3.494

Review 2.  Tendon injury and tendinopathy: healing and repair.

Authors:  Pankaj Sharma; Nicola Maffulli
Journal:  J Bone Joint Surg Am       Date:  2005-01       Impact factor: 5.284

3.  Expression of sensory neuropeptides in tendon is associated with failed healing and activity-related tendon pain in collagenase-induced tendon injury.

Authors:  Pauline Po-Yee Lui; Lai-Shan Chan; Sai-Chuen Fu; Kai-Ming Chan
Journal:  Am J Sports Med       Date:  2010-02-05       Impact factor: 6.202

4.  Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons.

Authors:  Lauren V Schnabel; Maureen E Lynch; Marjolein C H van der Meulen; Amy E Yeager; Matthew A Kornatowski; Alan J Nixon
Journal:  J Orthop Res       Date:  2009-10       Impact factor: 3.494

5.  New insights in extracellular matrix remodeling and collagen turnover related pathways in cultured human tenocytes after ciprofloxacin administration.

Authors:  Alessandra Menon; Letizia Pettinari; Carla Martinelli; Graziano Colombo; Nicola Portinaro; Isabella Dalle-Donne; Maria Cristina d'Agostino; Nicoletta Gagliano
Journal:  Muscles Ligaments Tendons J       Date:  2013-08-11

6.  Abnormal tenocyte morphology is more prevalent than collagen disruption in asymptomatic athletes' patellar tendons.

Authors:  J L Cook; J A Feller; S F Bonar; K M Khan
Journal:  J Orthop Res       Date:  2004-03       Impact factor: 3.494

7.  Can platelet-rich plasma enhance tendon repair? A cell culture study.

Authors:  Marieke de Mos; Anna E van der Windt; Holger Jahr; Hans T M van Schie; Harrie Weinans; Jan A N Verhaar; Gerjo J V M van Osch
Journal:  Am J Sports Med       Date:  2008-03-07       Impact factor: 6.202

Review 8.  Stem cell technology for tendon regeneration: current status, challenges, and future research directions.

Authors:  Pauline Po Yee Lui
Journal:  Stem Cells Cloning       Date:  2015-12-11

9.  Effects of corticosteroid on the expressions of neuropeptide and cytokine mRNA and on tenocyte viability in lateral epicondylitis.

Authors:  Soo Hong Han; Hee Jung An; Ji Ye Song; Dong Eun Shin; Young Do Kwon; Jong Sup Shim; Soon Chul Lee
Journal:  J Inflamm (Lond)       Date:  2012-10-30       Impact factor: 4.981

10.  Creating an Animal Model of Tendinopathy by Inducing Chondrogenic Differentiation with Kartogenin.

Authors:  Ting Yuan; Jianying Zhang; Guangyi Zhao; Yiqin Zhou; Chang-Qing Zhang; James H-C Wang
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more
  2 in total

1.  Inhibition of IKKβ/NF-κB signaling facilitates tendinopathy healing by rejuvenating inflamm-aging induced tendon-derived stem/progenitor cell senescence.

Authors:  Chongyang Wang; Zhekun Zhou; Wei Song; Zhuochang Cai; Zhenyu Ding; Daoyun Chen; Fangfang Xia; Yaohua He
Journal:  Mol Ther Nucleic Acids       Date:  2021-12-17       Impact factor: 8.886

2.  The expression of substance P and calcitonin gene-related peptide is associated with the severity of tendon degeneration in lateral epicondylitis.

Authors:  Soo-Hong Han; Hyung Kyung Kim; Yoon Jang; Hyeon Hae Lee; Jeongbae Rhie; Donghun Han; Jongbeom Oh; Soonchul Lee
Journal:  BMC Musculoskelet Disord       Date:  2021-02-21       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.